Trials / Conditions / Oropharynx Squamous Cell Carcinoma

Oropharynx Squamous Cell Carcinoma

21 registered clinical trials studyying Oropharynx Squamous Cell Carcinoma — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Canc NCT07063212	Memorial Sloan Kettering Cancer Center	Phase 2
Recruiting	SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve NCT05582122	UNICANCER	Phase 2
Recruiting	Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SA NCT06088381	University of Maryland, Baltimore	Phase 2
Withdrawn	A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor NCT04892875	Jennifer Choe	Phase 1
Recruiting	Monitoring and Early Response Evaluation Using HPV DNA - A Study on Patients With HPV-positive Throat Cancer ( NCT05649865	Region Skane	—
Recruiting	Detection of Oral and Throat Cancers Using OralViome Cancer Testing System NCT05451303	Viome	—
Recruiting	Training Swallowing Initiation During Expiration NCT05278039	Northwestern University	N/A
Terminated	A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With NCT04916002	Regeneron Pharmaceuticals	Phase 2
Recruiting	First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients NCT04858269	Wake Forest University Health Sciences	Phase 2
Completed	Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPC NCT04725396	UNICANCER	N/A
Active Not Recruiting	Circulating Biomarkers in Oropharyngeal Cancers NCT05904327	Region Örebro County	—
Recruiting	Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associ NCT04564989	UNC Lineberger Comprehensive Cancer Center	—
Completed	Collagen Matrix in Oral Cancer Surgery NCT07337122	SAYAH Charline	—
Unknown	QUantitative Assessment of Swallowing After Radiation (QUASAR) NCT04359199	Loren Mell, MD	—
Terminated	Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Ne NCT04445064	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	Phase 2
Completed	Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer NCT03829722	University of Michigan Rogel Cancer Center	Phase 2
Completed	IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma NCT03381183	H. Lee Moffitt Cancer Center and Research Institute	Phase 1
Active Not Recruiting	Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma NCT04124198	Christian von Buchwald	N/A
Completed	Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer NCT03715946	Robert L. Ferris, MD, PhD	Phase 2
Completed	Saliva-based Detection of CD44 NCT03148665	Joseph Califano	—
Unknown	Intensity-Modulated Proton Therapy (IMPT) or TransOral Robotic Surgery (TORS) for the Treatment of Low-Risk Or NCT02663583	M.D. Anderson Cancer Center	—